Should Roche Buy Exelixis?

A successful phase 3 study has started rumors that Roche may bid for Exelixis

Jul 16, 2014 at 5:00PM

Investors in Roche (NASDAQOTH:RHHBY) and Exelixis (NASDAQ:EXEL) saw a bit of positive news Monday, when Roche announced that its phase 3 combo study of MEK inhibitor cobimetinib (licensed from Exelixis) and BRAF inhibitor Zelboraf met it primary endpoint. No details were supplied, other than that the company is moving forward with regulatory filings in the U.S. and EU.

Although this combo therapy is not likely to move the needle too far for Roche, it could be significant for Exelixis and talk is now circulating that Roche may buy the company to capture full economics on the drug.

A successful pivotal study
Roche announced Monday morning that the "coBRIM" study met its primary endpoint and that patients with advanced melanoma lived "significantly longer" on the combo drug therapy of cobimetinib and Zelboraf (which is already approved). Roche intends to present the data later this year at a medical meeting, so there was minimal detail in the release. As a reminder, an earlier phase Ib study showed a 13.7-month improvement in progression-free survival and 10% of the patients getting the combo showed a complete response.

By way of comparison, the similar combination of GlaxoSmithKline's (NYSE:GSK) Tafinlar and Mekinist showed a 9.3-month improvement in progression-free survival in phase 3 testing. Overall survival data will likely be the more significant information from a competitive perspective.

How much potential is there?
Melanoma is highly survivable if caught and treated early, but it can be deadly in more advanced forms. Luckily it is not particularly common, with only about 10,000 cases diagnosed each year (in the U.S.) that have spread beyond the primary site.  With that, it's not an especially large market (around $1.5 billion to $2 billion a year in the U.S., Europe, and Japan) and it is also a popular target for new immuno-oncology therapies from Bristol-Myers Squibb (NYSE:BMY), Merck, Roche, and AstraZeneca.

Between competition from Bristol's Yervoy, Glaxo (soon to be Novartis') Tafinlar/Mekinst combo, and immunotherapies, I think it will be tough for Roche/Exelixis's combo therapy to become the go-to therapy for an extended length of time. Granted, I am making something of an apples-to-oranges comparison here, as not all of these treatments are/will be labeled for the same patients (the Roche combo will address the 40% to 50% of melanoma patients that have the BRAF V600 mutation).

I believe that $1 billion/year in revenue for 10 years would be quite an achievement, though the rate of inflation in drug prices does generate some upside to that figure. At Roche's current profit levels, that means $350 million in peak operating profits to split and given the splits specified in the agreement (a sliding scale of profits from 50% to 30% and low double-digit royalties on ex-US sales), I estimate about 30% going to Exelixis. Discounting that back at 8%, I come up with a value of just over $700 million for Exelixis's profit streams from cobimetinib.

Will Cometriq come through?
I think the above estimates for cobimetinib/Zelboraf are very aggressive and the company's development of Cometriq is a bigger driver today. Getting approval in prostate cancer (the COMET-1 and COMET-2 studies) would be significant, particularly as part of a combo, as would second-line liver cancer (the kidney cancer application is less promising with the emerging competition from immuno-oncology therapies). 

With a current enterprise value of over $850 million, I don't see a compelling value for Roche in buying Exelixis solely on the basis of controlling 100% economics on the melanoma combo therapy. Roche management may well have a more bullish outlook on Exelixis's pipeline and that changes the argument, but cobimetinib alone isn't enough. Add in some additional (substantial) potential value from these label extension studies for Cometriq and the argument for owning Exelixis gets stronger ... but that's predicated on successful trial results.

The bottom line
Later data releases on the coBRIM study will help refine the market potential of cobimetinib and Zelboraf further, as will additional data from immuno-oncology studies (including combo studies). As is, it's a welcome positive for Exelixis and should bring in some cash starting next year. For Roche it is a smaller positive, though still a positive all the same and a reminder that this oncology giant is about more than just mature antibody therapies and developmental immuno-oncology projects.

Warren Buffett: This new technology is a "real threat"
At the recent Berkshire Hathaway annual meeting, Warren Buffett admitted this emerging technology is threatening his biggest cash-cow. While Buffett shakes in his billionaire-boots, only a few investors are embracing this new market which experts say will be worth over $2 trillion. Find out how you can cash in on this technology before the crowd catches on, by jumping onto one company that could get you the biggest piece of the action. Click here to access a FREE investor alert on the company we're calling the "brains behind" the technology.

Stephen D. Simpson, CFA owns shares of Roche. The Motley Fool recommends Exelixis. The Motley Fool owns shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers